Overview
Karuna Therapeutics developed KarXT (xanomeline-trospium), a novel muscarinic receptor-based treatment for schizophrenia that received FDA approval in 2024 under the brand name Cobenfy, representing the first new mechanism of action for schizophrenia in decades. Karuna was acquired by Bristol Myers Squibb in 2024 for approximately $14 billion.
More in Neuropharmaceuticals
Latest industry news
Generative AI Is Closing the Gap on Brain-Computer Interface Accuracy and Resolution
2026-11-11 ยท Research
Spiking Neural Networks Emerge as a Viable Shield Against Signal Noise in Brain-Computer Interfaces
2026-11-10 ยท Research
China's Brain-Reading Device Hits 94% Mind-Typing Accuracy Over a Full Day of Use
2026-11-09 ยท Research
Wearable Brain-Computer Interfaces Are Closer to Mainstream Than You Think
2026-11-08 ยท Industry
Company details
Category
๐ Neuropharmaceuticals
Location
Boston, USA
Funding
Acquired ยท Bristol Myers Squibb 2024
Website
www.karunatx.comListed
2026-06-15
Is this your company?
Claim this listing to add your logo, full description, team, and products. Premium listings get featured placement.
Claim & upgrade listingAdvertise
Reach neurotech professionals
Newsletter sponsorships, featured listings, and sponsored articles.
View packages โ